Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as the new Greater China Chief Commercial Officer (CCO), succeeding Liang Yi, who is departing from his role as both CCO and President of Greater China. Liang’s departure will become official on April 30.
Zhu Tong’s career in the pharmaceutical industry began in 2001 after his graduation from Zhejiang University, when he joined Roche as a pharmaceutical representative. He progressed through the ranks, holding various positions at Novartis and Bristol-Myers Squibb, including Product Manager, Marketing Manager, and Regional Sales Manager. From 2015 to 2017, Zhu served as the Marketing Director at AstraZeneca. In 2017, he moved to Sanofi China as the Head of the Internal Medicine Division. Zhu rejoined AstraZeneca in 2019 as the Assistant Vice President and Head of Cardiovascular Therapy. Between 2020 and 2021, he held multiple leadership roles at AstraZeneca China, including Vice President, Head of Cardiovascular and Metabolic Business Unit, and Head of Cardiovascular, Renal, and Metabolic Business Unit. In 2022, Zhu left AstraZeneca and joined Simcere Pharmaceutical Group in April of the same year.
Liang Yi brings 24 years of oncology marketing experience to his new endeavors, having previously served as the Director of Roche Hong Kong’s Oncology Business Unit, Director of Business Operations at Abbott (NYSE: ABT) China, and Vice President of China’s Oncology Business Unit at BMS. In June 2014, Liang transitioned to AstraZeneca (NASDAQ: AZN) China as the Vice President and Head of the Oncology Business Unit. He joined Zai Lab in June 2018 as the Chief Business Officer and President of Greater China, where he built the company’s commercialization team and led the launch and sales of several significant products over the past six years.- Flcube.com
